GE HealthCare Technologies Inc. (GEHC) falls on deep earnings analysis
April 29, 202610 min read
Key Takeaway
GE HealthCare Technologies Inc. (GEHC) reported stronger-than-expected revenue but weaker profit, with adjusted EPS of $0.99 missing estimates and adjusted EBIT margin falling to 13.5%. The company kept organic sales guidance intact but cut 2026 EPS outlook to $4.80-$5.00, signaling that inflation, tariffs, and a supplier recall are weighing on margins even as demand remains healthy.
GE HealthCare Technologies Inc. (GEHC) falls hard after its latest earnings report showed a familiar split: revenue held up, but profit did not. The company posted adjusted EPS of $0.99, below the $1.07 consensus, while revenue of $5.13B topped the $5.03B estimate, and the stock dropped 13.75% during the regular session as investors focused on a lower full-year profit outlook.
Key Takeaways
GEHC earnings missed on profit but beat on sales, with adjusted EPS of $0.99 versus a $1.07 estimate and revenue of $5.13B versus a $5.03B estimate.
Pharmaceutical Diagnostics stood out as the strongest operating segment in the quarter, with 9.7% organic revenue growth, while Patient Care Solutions declined 8.1% organically and saw a 500 basis point EBIT margin drop.
Management kept 2026 organic sales growth guidance at 3% to 4% but cut adjusted EPS guidance to $4.80 to $5.00 and set adjusted EBIT margin guidance at 15.4% to 15.7%.
CEO Peter Arduini said demand stayed healthy, with solid orders, book-to-bill of 1.07x, and a record backlog of $21.8B, but he also said inflation and a PDx supplier recall hurt profit performance.
CFO Jay Saccaro said GEHC faced roughly $250M of gross inflation pressure in 2026, including about $100M from memory chips, $100M from oil and freight, and about $50M from other inputs such as metals.
Analyst sentiment was already mixed before the print, with the broader Wall Street consensus still at Buy, but recent target cuts from Piper Sandler and Citi and a Sell rating from UBS framed a more cautious setup into the report.
The headline in this GE HealthCare Technologies Inc. earnings analysis is straightforward. GEHC delivered better-than-expected revenue, but the margin story broke the quarter. Adjusted EPS of $0.99 missed consensus by $0.08, while revenue of $5.13B beat by $0.10B. That mismatch matters because investors usually forgive a small earnings miss when demand is weak. They do not forgive a guidance cut tied to cost pressure when demand is still healthy.
Quarterly revenue rose from $4.78B in the year-ago quarter to $5.13B in the March 2026 quarter. However, net income fell to $0.39B from $0.56B a year earlier. GAAP EPS in the quarterly financials was $0.85, down from $1.23 in the prior-year quarter. That gap between revenue growth and profit decline explains why the market treated this as a margin reset, not a growth story.
CFO Jay Saccaro said first-quarter revenue represented 2.9% organic growth and landed at the high end of internal expectations. He also said product revenue rose 7.3% and service revenue rose 7.5%. Orders increased 1.1%, book-to-bill was 1.07x, and backlog reached a record $21.8B, up $1.2B year over year. Those are healthy demand markers. Still, they were not enough to offset the earnings pressure.
We were disappointed with the adjusted EBIT margin of 13.5% and adjusted EPS of $0.99. Of note, adjusted EPS included approximately $0.16 of tariff impact. — Jay Saccaro, CFO, earnings call
Adjusted EBIT margin was 13.5%, down about 150 basis points year over year. Saccaro said the largest tariff impact for 2026 hit in the first quarter due to the timing of 2025 policy changes. He also pointed to weakness in Patient Care Solutions and the Pharmaceutical Diagnostics supplier issue as margin drags. In plain English, GEHC sold enough equipment and services, but the cost to build and deliver those products rose faster than expected.
Segment detail sharpened that picture. Imaging posted 3.8% organic revenue growth, helped by strong demand in the U.S. and EMEA, especially in CT and X-ray. Advanced Visualization Solutions grew 4.4% organically, with EBIT margin up 120 basis points year over year. Pharmaceutical Diagnostics delivered the best top-line result, with 9.7% organic growth driven by contrast media, price execution, and radiopharmaceutical demand. By contrast, Patient Care Solutions fell 8.1% organically, with management saying some large monitoring installations were weighted to the second half of the year.
PCS was the weak spot that investors could not ignore. The segment's EBIT margin fell 500 basis points year over year, reflecting lower volume and tariff pressure. Management said segment orders still grew and pointed to expected U.S. clearance for a new premium anesthesia product in the third quarter. Even so, the quarter showed that GEHC has less room for error when one business slows and input costs jump at the same time.
There were also a few notable line items outside the income statement. Free cash flow was $112M, up $13M year over year. GEHC completed the Intelerad acquisition, repaid $500M of debt, paid its dividend, and repurchased about $100M of stock. Those moves show balance-sheet discipline, but on earnings day, the market cared far more about the lower profit path than capital allocation polish.
Market Reaction and Analyst Response to GEHC Earnings
The market reaction was blunt. GEHC shares fell more than 9% in premarket trading after the report, according to Reuters coverage carried by Investing.com. The selling continued into the regular session, with the stock down 13.75% to $59.08 by mid-afternoon on April 29. Volume reached 19.7M shares versus an average of 3.59M, which shows this was not a quiet drift lower. It was a full repricing.
That reaction lines up with the central issue in the GEHC earnings call. Revenue was fine. Demand signals were fine. Guidance on sales stayed intact. But full-year profit guidance moved lower because inflation and tariffs hit harder than management expected. When a stock trades on margin expansion and execution, a profit reset tends to matter more than a modest revenue beat.
Analyst positioning already hinted at caution before the quarter. The current consensus still stands at Buy, with 11 Buy ratings, 5 Hold ratings, and 1 Sell rating. However, several firms had already been trimming expectations. Piper Sandler cut its price target to $88 from $96 on April 17 while keeping an Overweight rating. Citi lowered its target to $84 from $88 on March 11. UBS downgraded GEHC to Sell from Neutral on January 15 and set a $77 target, up from $73, citing valuation concerns after a rebound in the shares.
That setup matters because it shows the Street was not walking into this quarter with clean optimism. Some analysts had already started lowering the bar. Even so, the guidance cut was enough to trigger another leg down. The stock's move says investors now want proof that pricing and cost actions can offset inflation before they give GEHC credit for backlog, innovation, or recurring service revenue.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
CEO Peter Arduini framed the quarter as a demand story that got hit by a cost shock. His core message was that customer activity stayed healthy across major regions and product lines, but profit performance did not keep up because inflation accelerated and a supplier recall hit PDx.
As we think about the capital equipment backdrop, we're seeing healthy customer demand globally with resilient procedure growth. Aligned to this, we saw solid performance in orders, book-to-bill and backlog. — Peter Arduini, CEO, earnings call
Arduini also gave the clearest explanation for the guidance cut. He said GEHC began to see more significant increases in material costs later in the quarter and expects those pressures to continue through the rest of 2026. He quantified the problem in unusual detail, which is often what management does when it wants investors to understand that the issue is real, not cosmetic.
Later in the quarter, we began to see more significant increases in material costs, which we expect will continue for the remainder of the year. — Peter Arduini, CEO, earnings call
Arduini said the gross inflation hit for 2026 is about $250M, including about $100M from memory chips, about $100M from oil and freight, and about $50M from other inputs such as metals. He added that GEHC expects to offset more than half of that pressure with price and cost actions, but not enough to avoid a lower EPS outlook for this year.
On strategy, Arduini highlighted several growth projects. He pointed to regulatory clearances for Photonova Spectra in photon-counting CT, new FDA clearances in MR, continued Flyrcado dose growth, and the Intelerad acquisition. He also announced a segment reorganization that combines Imaging and Advanced Visualization Solutions into Advanced Imaging Solutions. The logic is simple: tie imaging hardware, workflow, and software together more tightly and reduce friction in the operating model.
CFO Jay Saccaro handled the financial side with less poetry and more arithmetic, which was exactly what the market needed. He kept top-line guidance at 3% to 4% organic sales growth, but cut adjusted EPS guidance to $4.80 to $5.00 and set adjusted EBIT margin guidance at 15.4% to 15.7%.
We're also reducing our adjusted EPS guidance to a range of $4.80 to $5 per share, which represents approximately 5% to 9% growth year-over-year. — Jay Saccaro, CFO, earnings call
Saccaro also said GEHC does not expect a material benefit in 2026 from tariff policy changes announced earlier this year. That comment likely mattered more than it first looked. It told investors not to assume a policy rescue will fix the margin problem in the back half.
Analyst Q and A Highlights From the GEHC Earnings Call
The transcript excerpt provided does not include the analyst Q and A portion with named analyst exchanges. What is still clear from management's prepared remarks is where analysts were most likely pressing: why profit guidance fell while demand stayed solid, how much of the inflation hit GEHC can really offset, and whether China and PCS create added risk on top of tariffs and input costs.
The most revealing management defense centered on the inflation bridge. Arduini said the gross impact is about $250M, or $0.43 per share, and that GEHC expects to offset more than half through price and cost actions. Saccaro then translated that into a smaller, but still meaningful, full-year EPS reduction. That pairing matters because it shows management is not calling this a collapse in demand. It is calling it a cost absorption problem.
Prior to any mitigation, the gross impact of these costs is approximately $250 million or $0.43 per share. We expect to offset more than half of the inflation impact in 2026 with price and cost actions. — Peter Arduini, CEO, earnings call
Another revealing point was the split between healthy order activity and weak profit conversion. Saccaro said orders grew 1.1%, book-to-bill was 1.07x, and backlog hit $21.8B. Yet adjusted EBIT margin still fell to 13.5%. That is the kind of disconnect analysts usually challenge because it tests whether backlog quality and pricing power are strong enough to protect future earnings.
A third issue was Patient Care Solutions. Management said the 8.1% organic decline reflected large monitoring installations weighted to the second half, while segment orders still grew. That answer defends the revenue timing issue, but the 500 basis point margin decline means analysts are still likely to treat PCS as a pressure point until backlog conversion improves in reported results.
Bottom Line
GEHC earnings showed that demand for GE HealthCare Technologies Inc. products remains intact, but the company lost control of the cost side in the quarter. For investors, the next step is simple: GEHC now needs to prove that pricing, cost actions, and backlog conversion can rebuild margins fast enough to support the new $4.80 to $5.00 EPS range.
Until that happens, the stock's sharp fall makes sense. In this report, revenue was the steady hand, but guidance was the verdict.
+Why did GE HealthCare (GEHC) stock fall after earnings?
GE HealthCare fell 13.75% because investors focused on the profit miss and lower full-year outlook, not the revenue beat. Adjusted EPS came in at $0.99 versus $1.07 expected, and management cut 2026 adjusted EPS guidance to $4.80-$5.00.
+Did GE HealthCare beat revenue and miss earnings in the latest quarter?
Yes. GE HealthCare reported revenue of $5.13 billion versus the $5.03 billion consensus estimate, but adjusted EPS was $0.99 versus the $1.07 estimate. The quarter showed solid demand, but margins were pressured by inflation, tariffs, and a supplier recall.
+What is GE HealthCare's updated 2026 guidance?
GE HealthCare kept 2026 organic sales growth guidance at 3% to 4%. It lowered adjusted EPS guidance to $4.80 to $5.00 and set adjusted EBIT margin guidance at 15.4% to 15.7%.
+Which GE HealthCare segment performed best and which was weakest?
Pharmaceutical Diagnostics was the strongest segment, with 9.7% organic revenue growth driven by contrast media, pricing, and radiopharmaceutical demand. Patient Care Solutions was the weakest, with 8.1% organic revenue decline and a 500 basis point drop in EBIT margin.
Want the full picture on GEHC?
Read the analyst-grade research report — charts, grades, and price targets.
